FDA Asks for Input on Post-Market Drug Safety Reporting
Published Date: 5/13/2026
Notice
Summary
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
Analyzed Economic Effects
6 provisions identified: 1 benefits, 5 costs, 0 mixed.
Mandatory ICH E2B(R3) Data Standard
If you submit postmarketing individual case safety reports (ICSRs) via FDA's Electronic Submissions Gateway Next Generation (ESG NextGen), those ICSRs must use the ICH E2B(R3) data standards beginning October 1, 2026. FDA began accepting E2B(R3) voluntarily in January 2024 and is now requiring the R3 standard on that date.
10- and 6-Year Recordkeeping Rules
Applicants and manufacturers must keep adverse drug experience records for 10 years under 21 CFR 314.80(j) and 310.305(g). For nonprescription human drug products under section 760(e), responsible persons must retain nonprescription adverse event records for 6 years.
Enhanced Pharmacovigilance Requests by FDA
FDA's January 2024 'Best Practices' may lead to enhanced pharmacovigilance activities for specific products; FDA may request use of targeted data collection tools, expedited submission of adverse experiences beyond minimum reporting, and summarization/assessment at FDA-defined frequencies. FDA has included burden estimates for these enhanced activities in its tables.
Periodic Report Timing Requirement
For approved drug applications, periodic postmarketing safety reports must be submitted quarterly for the first 3 years after U.S. approval and annually thereafter, per 21 CFR 314.80(c)(2) and 600.80(c)(2). These reports must include narratives, summaries, analyses, and indexes of adverse experiences.
5-Day Combination-Product Notification Rule
If a combination product event involves a drug and a constituent applicant receives information about a death, serious injury, or adverse event, that information must be provided to other constituent part applicants no later than 5 calendar days after receipt under 21 CFR 4.103. Rules for submission and recordkeeping for combination products are in 21 CFR 4.104 and 4.105.
Electronic Submission Waivers for Good Cause
All reports and followup reports generally must be submitted electronically, but FDA may grant temporary waivers of the electronic submission requirements for good cause. Waiver requests can be submitted under the cited regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13139 — Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of Hyperhidrosis
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Previous / Next Documents
Previous: 2026-09542 — Agency Information Collection Activity Under OMB Review: Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program (SSG Fox SPGP)
The VA is renewing its paperwork for the Staff Sergeant Parker Gordon Fox Suicide Prevention Grant Program, which helps communities support veterans at risk of suicide. This means organizations applying for or renewing grants will keep submitting forms to show how they’re helping and following rules. If you’re involved, get ready to send your feedback by June 12, 2026, so the program can keep saving lives smoothly and smartly.
Next: 2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.